^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Solid Tumor
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

    Excerpt:
    Inclusion Criteria: BRCA1, BRCA2 and/or ATM gene defect.
    Trial ID:
    NCT03565991